Brief: AIM Immunotech Analysis Of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential To Improve Post-Covid Condition Of Fatigue
11/09/2024 15:57
Sept 11 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH: ANALYSIS OF AMP-518 COMPLETE CLINICAL
PATIENT
DATA UNDERSCORES AMPLIGEN'S POTENTIAL TO IMPROVE POST-COVID
CONDITION OF FATIGUE
Source text for Eikon: ID:nGNX8PFJ3N
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential